Sanofi Completes Acquisition of Blueprint Medicines to Boost Rare Disease Portfolio
Sanofi has finalized its acquisition of Blueprint Medicines, enhancing its portfolio in rare disease treatments.
Key Points
- • Sanofi completes acquisition of Blueprint Medicines on July 18, 2025.
- • Acquisition includes Ayvakit/Ayvakyt, the first treatment for systemic mastocytosis.
- • Financed through available cash and treasury notes, with no significant impact on 2025 forecasts.
- • Shares of Blueprint Medicines will be delisted from NASDAQ post-acquisition.
On July 18, 2025, Sanofi officially announced the finalization of its acquisition of Blueprint Medicines Corporation, a strategic move aimed at enhancing its portfolio focused on rare diseases, specifically systemic mastocytosis (SM). This acquisition includes the acquisition of Ayvakit/Ayvakyt (avapritinib), recognized as the first and only approved treatment for advanced and indolent SM, alongside a novel generation medication, elenestinib, currently in clinical trials. Sanofi also obtained BLU-808, an experimental oral inhibitor.
The transaction was financed using available cash and the issuance of treasury notes, ensuring it will not significantly affect Sanofi's financial forecasts for 2025. However, it is expected to have an immediate positive impact on the company's gross margin and operating profit post-2026. The shares of Blueprint Medicines will be delisted from NASDAQ following the completion of this deal, with shareholders receiving $129.00 per share, in addition to potential contingent payments.
This acquisition aligns with Sanofi's broader strategy to innovate within immunology and address the unmet needs of patients suffering from rare diseases, emphasizing the company’s commitment to enhance its therapeutic offerings in this crucial market segment.